Publication | Closed Access

Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease

Retrospective Comparative StudyAutoimmune DiseaseInflammatory Lung DiseaseAdvanced Lung DiseaseSystemic SclerodermaImmunologyPulmonary FibrosisPulmonary MedicineSclerodermaMedicineNovel TherapyJak Inhibitor